Patents by Inventor John Hakimi

John Hakimi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11966982
    Abstract: Methods and systems for automatically mitigating risks of insurance-related events to a property are provided. According to certain aspects, a smart home controller or insurance provider remote processor may analyze data received from a plurality of smart devices disposed on, within, or proximate to a property, as well as data received from an insurance provider. If it is determined that an actual or potential risk of property damage exists, the smart home controller or insurance provider remote processor may automatically issue commands to one or more smart devices to take actions that mitigate the risk. The smart home controller may also transmit information about the actual or potential risks and any mitigative actions to an insurance provider. The insurance provider remote processor may interpret the transmitted data to perform insurance activities, such as providing a discount and/or adjusting an insurance premium or policy associated with the property.
    Type: Grant
    Filed: May 31, 2022
    Date of Patent: April 23, 2024
    Assignee: STATE FARM MUTUAL AUTOMOBILE INSURANCE COMPANY
    Inventors: Ronny S. Bryant, Shawn M. Call, Daryoush Hakimi-Boushehri, John H. Weekes, Jennifer Criswell, Todd Binion, Jackie O. Jordan, II, Elisabeth McDermeit, John Donovan
  • Patent number: 5849860
    Abstract: The present invention is a physiologically active, substantially non-immunogenic water soluble polyethylene glycol protein conjugate having the same utility as the protein which forms the conjugate, without having the same properties of producing an immunogenic response possessed by the protein which forms this conjugate.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: December 15, 1998
    Assignee: Hoffmann-La Roche Inc.
    Inventors: John Hakimi, Patricia Kilian, Perry Rosen
  • Patent number: 5834594
    Abstract: The present invention is a physiologically active, substantially non-immunogenic water soluble polyethylene glycol protein conjugate having the same utility as the protein which forms the conjugate, without having the same properties of producing an immunogenic response possessed by the protein which forms this conjugate.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: November 10, 1998
    Assignee: Hoffman-La Roche Inc.
    Inventors: John Hakimi, Patricia Kilian, Perry Rosen
  • Patent number: 5792834
    Abstract: The present invention is a physiologically active, substantially non-immunogenic water soluble polyethylene glycol protein conjugate having the same utility as the protein which forms the conjugate, without having the same properties of producing an immunogenic response possessed by the protein which forms this conjugate.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: August 11, 1998
    Assignee: Hoffmann-La Roche Inc.
    Inventors: John Hakimi, Patricia Kilian, Perry Rosen
  • Patent number: 5747646
    Abstract: The present invention is a physiologically active, substantially non-immunogenic water soluble polyethylene glycol protein conjugate having the same utility as the protein which forms the conjugate, without having the same properties of producing an immunogenic response possessed by the protein which forms this conjugate.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: May 5, 1998
    Assignee: Hoffmann-La Roche Inc.
    Inventors: John Hakimi, Patricia Kilian, Perry Rosen
  • Patent number: 5650492
    Abstract: Analysis of the culture media of p40-transfected COS cells indicated the presence of 40 kDa monomers and 80 kDa disulfide-linked homodimers. Examination of partially purified p40 recombinant proteins demonstrated that only the homodimer but not the monomer binds to the IL-12 receptor. Partially purified 80 kDa homodimer inhibited [.sup.125 I]IL-12 binding to PHA-activated human lymphoblasts with an IC.sub.50 of 80 ng/ml, which is similar to the IC.sub.50 value (20 ng/ml) for the human IL-12 heterodimer. Although neither the 40 kDa monomer nor the 80 kDa dimer could stimulate human PHA-blast proliferation, the 80 kDa dimer inhibited IL-12-induced proliferation in a dose-dependent manner with an IC.sub.50 of 1 .mu.g/ml. The IL-12 p40 subunit contains the essential epitopes for receptor binding, but they are only active when p40 is covalently associated with a second protein such as p35 or p40. When p40 is associated with the p35 subunit, the heterodimer acts as an agonist mediating biologic activity.
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: July 22, 1997
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maurice Kent Gately, John Hakimi, Ping Ling
  • Patent number: 5559213
    Abstract: The present invention is a physiologically active, substantially non-immunogenic water soluble polyethylene glycol protein conjugate having the same utility as the protein which forms the conjugate, without having the same properties of producing an immunogenic response possessed by the protein which forms this conjugate.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: September 24, 1996
    Assignee: Hoffmann-La Roche Inc.
    Inventors: John Hakimi, Patricia Kilian, Perry Rosen
  • Patent number: 5539063
    Abstract: The present invention is a polymer which may be used to produce a physiologically active, substantially non-immunogenic water soluble polyethylene glycol protein conjugate having the same utility as the protein which forms the conjugate, without having the same properties of producing an immunogenic response possessed by the protein which forms this conjugate.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: July 23, 1996
    Assignee: Hoffmann-La Roche Inc.
    Inventors: John Hakimi, Patricia Kilian, Perry Rosen